The Colorado Attorney General’s Office announced Thursday that the owner of Loveland Medical Clinic has been ordered to pay $ 40,000 for violating a cease-and-desist order that required him to stop marketing bogus COVID remedies. -19.
However, Siegfried Emme, the owner of the clinic, will only owe $ 20,000 if he complies with the order, according to a consent judgment filed in Larimer County District Court.
“False advertising of so-called ‘cures’ and the provision of misleading information about COVID-19 treatments can directly harm patients and prevent them from seeking the care they need,” said Attorney General Phil Weiser in a press release.
In March 2020, Emme began advertising intravenous therapies as treatments for the COVID-19 virus. Eventually, he started promoting other treatments, including ivermectin, an antiparasitic drug often used in animals, and overestimated their effectiveness against the virus, according to the attorney general’s office.
Emme made the statements on social media and an online blog. He rarely issued warnings that his articles were “misleading and frequently contradicted the blog posts themselves,” according to a press release.
The Colorado Department of Law issued a cease-and-desist order last November, in which it agreed to remove the deceptive posts, but failed to remove all of them, officials said.
Several articles on Loveland Medical Clinic Facebook page had several messages, indicating the effectiveness of ivermectin as of 5:30 p.m. Thursday.
In addition to paying the fine of $ 40,000, Emme agreed to:
- Not to make any false or misleading statements in connection with the sale of health or medical services in Colorado;
- Do not make false, misleading, or unsubstantiated claims about the effectiveness of your therapies as treatments or preventative measures for COVID-19. This includes, but is not limited to, false, misleading, or unfounded representations regarding Ivermectin, the MAT + protocol, the I-Mask protocol, or intravenous vitamin therapy as treatments or preventative measures for COVID-19; and
- Clearly disclose treatments if they are approved by the Food and Drug Administration, if they are recommended by the National Institute of Health, if there are any warnings or associated notices by any federal or state government agency regarding the treatment or preventive measure, and whether the treatment is experimental.